Skip to main content

N-linked glycosylation regulates SNAT2 trafficking and stability in pancreatic ductal adenocarcinoma cells.

Koe JC, Pashaoskooie K, Johal D, Zhong YC, Wu C, Parker SJ
Am J Physiol Cell Physiol. 2026 Jun 29. doi: 10.1152/ajpcell.00060.2026. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

ID Plasmid Purpose
237226pLenti CMV SNAT2-eGFP WT (wildtype)Lentiviral destination vector expressing sgRNA-resistant wildtype SNAT2 (SLC38A2) cDNA containing C-terminal eGFP.
237227pLenti CMV SNAT2-eGFP 3NQLentiviral destination vector expressing sgRNA-resistant SNAT2 (SLC38A2) cDNA containing C-terminal eGFP. SNAT2 sequence contains mutations to inhibit N-linked glycosylation.
237228pInducer20 SNAT2-eGFP WT (wildtype)Lentiviral vector expressing dox-inducible sgRNA-resistant wildtype SNAT2 (SLC38A2) cDNA containing C-terminal eGFP.
237229pInducer20 SNAT2-eGFP 3NQLentiviral vector expressing dox-inducible sgRNA-resistant SNAT2 (SLC38A2) cDNA containing C-terminal eGFP. SNAT2 sequence contains mutations to inhibit N-linked glycosylation.
237230pLenti CRISPRv2 sgSLC38A2#1Plasmid for SNAT2 (SLC38A2) CRISPR knockout in human cell lines.
237231pDONR221 SNAT2-eGFP WT (wildtype)Donor vector for gateway cloning of sgRNA-resistant wildtype SNAT2 (SLC38A2) cDNA sequence containing C-terminal eGFP.
237232pDONR221 SNAT2-eGFP 3NQDonor vector for gateway cloning of sgRNA-resistant SNAT2 (SLC38A2) cDNA sequence containing C-terminal eGFP. SNAT2 sequence contains mutations to inhibit N-linked glycosylation.

Antibodies from Article